Methods and compositions for treating keratin hyperproliferative disorders
A method for keratin hyperproliferation disorders such as corns, calluses, or keratosis pilaris (KP) by administering to a subject experiencing the disorder a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17, and combinations thereof.
1. A method of treating a hyperproliferation skin disorder in a subject who is manifesting a hyperproliferation disorder, comprising:
administering to the subject who is manifesting a hyperproliferation disorder selected from the group consisting of keratosis pilaris, calluses, corns, psoriasis, keratosis follicularis, pityriasis rubra pilaris, and Clouston syndrome, a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17, and combinations thereof, wherein the inhibited gene encodes the K6a keratin and the RNA sequence is a member selected from the group consisting of: SEQ. ID NO: 2, SEQ. ID NO: 4, SEQ. ID NO: 6, SEQ. ID NO: 8, SEQ. ID NO: 10, SEQ. ID NO: 12, SEQ. ID NO: 14, SEQ. ID NO: 16, SEQ. ID NO: 18, SEQ. ID NO: 20, SEQ. ID NO: 86, SEQ. ID NO: 91, SEQ. ID NO: 92, SEQ. ID NO: 94, and combinations thereof.
2. The method of claim 1 , wherein the hyperproliferation skin disorder is keratosis pilaris.
3. The method of claim 1 , wherein the hyperproliferation skin disorder is a callus.
4. The method of claim 1 , wherein the hyperproliferation skin disorder is a corn.
5. The method of claim 1 , wherein the RNA sequence is a small interfering RNA.
6. The method of claim 1 , wherein the subject's overexpressed gene encodes keratin 6a (K6a).
7. The method of claim 1 , wherein the RNA sequence is administered as double stranded RNA.
8. The method of claim 1 , wherein the RNA sequence is administered as a short hairpin RNA.
9. The method of claim 1 , wherein the RNA sequence has a length of about 15 to about 31 nucleotides.
10. The method of claim 1 , wherein the RNA sequence is administered transdermally.
11. The method of claim 10 , wherein the transdermal administration includes formulations and processes selected from the group consisting of: a lotion, a cream, a gel, an ointment, a paste, a transdermal patch, a liposome, iontophoresis, electroporation, sonophoresis, or combinations thereof.
12. The method of claim 1 , wherein the RNA sequence is administered by intradermal injection.
13. The method of claim 12 , wherein the intradermal injection is accomplished using dissolvable needles.
14. The method of claim 1 , wherein the RNA sequence is administered in a therapeutically effective amount of from about 0.1 mg to about 10 mg.
15. The method of claim 1 , wherein the RNA sequence contains at least one modified nucleotide.
16. The method of claim 1 , wherein the RNA sequence is administered in combination with a therapeutically effective amount of a compound selected from the group consisting of corticosteroid, lanolin, aloe vera, urea, propylene glycol, a-hydroxy acids, lactic acid, salicylic acid, vitamin D 3 and its derivatives, vitamin A and retinoids, levothyroxin, NSAIDS, cyclosporine, methotrexate sodium, anthralin, acitretin, tazarotene, coal tar, botulinum toxin, topical anesthetics, antihistamine, and combinations thereof.
17. The method of claim 1 , wherein the inhibited gene encodes for a mutated keratin.
18. The method of claim 1 , wherein the inhibited gene encodes a wildtype keratin.
19. The method of claim 15 , wherein the RNA sequence inhibits expression of both mutated and wildtype keratin genes.
20. The method of claim 1 , further comprising the step of selecting a subject who manifests a hyperproliferation skin disorder selected from the group consisting of keratosis pilaris, calluses, corns, psoriasis, keratosis follicularis, pityriasis rubra pilaris, and Clouston syndrome.
21. The method of claim 1 , wherein the RNA sequence comprises SEQ. ID NO: 94.